Literature DB >> 26238486

mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells.

Charlotte M Huijts1, Famke L Schneiders2, Juan J Garcia-Vallejo3, Henk M Verheul2, Tanja D de Gruijl2, Hans J van der Vliet1.   

Abstract

CD1d-restricted activation of invariant NKT (iNKT) cells results in the abundant production of various types of cytokines and the subsequent modulation of immune responses. This has been shown to be relevant in several clinical disorders, including cancer, autoimmunity, and graft tolerance. Although it is well known that the suppressive function of regulatory T cells is critically dependent on the FOXP3 gene, FOXP3 can also be expressed by conventional human T cells upon activation, indicating the lack of specificity of FOXP3 as a marker for suppressive cells. In this study, we report that the mammalian target of rapamycin (mTOR) inhibitor rapamycin and IL-10, but not TGF-β, can induce FOXP3 expression in iNKT cell lines. Importantly, however, FOXP3(+) iNKT cells only acquired suppressive abilities when cultured in the presence of the mTOR inhibitor rapamycin. Suppression of responder T cell proliferation by FOXP3(+) iNKT cells was found to be cell contact-dependent and was accompanied by a reduced capacity of iNKT cells to secrete IFN-γ. Notably, imaging flow cytometry analysis demonstrated predominant nuclear localization of FOXP3 in suppressive FOXP3(+) iNKT cells, whereas nonsuppressive FOXP3(+) iNKT cells showed a predominance of cytoplasmically localized FOXP3. In conclusion, whereas IL-10 can enhance FOXP3 expression in iNKT cells, mTOR inhibition is solely required for promoting nuclear localization of FOXP3 and the induction of suppressive FOXP3(+) iNKT cells.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26238486     DOI: 10.4049/jimmunol.1402710

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.

Authors:  Iraia García-Santisteban; Igor Arregi; Marián Alonso-Mariño; María A Urbaneja; Juan J Garcia-Vallejo; Sonia Bañuelos; Jose A Rodríguez
Journal:  Cell Mol Life Sci       Date:  2016-06-16       Impact factor: 9.261

Review 2.  Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.

Authors:  David A Horwitz; Tarek M Fahmy; Ciriaco A Piccirillo; Antonio La Cava
Journal:  Trends Immunol       Date:  2019-10-07       Impact factor: 16.687

Review 3.  Immune Regulation in Pregnancy: A Matter of Perspective?

Authors:  Elizabeth A Bonney
Journal:  Obstet Gynecol Clin North Am       Date:  2016-10-14       Impact factor: 2.844

Review 4.  New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.

Authors:  Matthias Waldner; Daniel Fantus; Mario Solari; Angus W Thomson
Journal:  Br J Clin Pharmacol       Date:  2016-03-06       Impact factor: 4.335

5.  West Nile virus-infected human dendritic cells fail to fully activate invariant natural killer T cells.

Authors:  S Kovats; S Turner; A Simmons; T Powe; E Chakravarty; J Alberola-Ila
Journal:  Clin Exp Immunol       Date:  2016-09-22       Impact factor: 4.330

6.  Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.

Authors:  Kelly Andrews; Anouk A J Hamers; Xiaodian Sun; Geoffrey Neale; Katherine Verbist; Paige Tedrick; Kim E Nichols; Shalini Pereira; Daniel E Geraghty; Asha B Pillai
Journal:  Cytotherapy       Date:  2020-03-29       Impact factor: 5.414

Review 7.  mTOR Regulation of Lymphoid Cells in Immunity to Pathogens.

Authors:  Rachael Keating; Maureen Ann McGargill
Journal:  Front Immunol       Date:  2016-05-11       Impact factor: 7.561

8.  A Novel Forkhead Box Protein P (FoxP) From Litopenaeus vannamei Plays a Positive Role in Immune Response.

Authors:  Jiefeng Gao; Ran Geng; Hengwei Deng; Hongliang Zuo; Shaoping Weng; Jianguo He; Xiaopeng Xu
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 9.  Harnessing invariant natural killer T cells to control pathological inflammation.

Authors:  Nikhila S Bharadwaj; Jenny E Gumperz
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

Review 10.  Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.

Authors:  Dorian Stolk; Hans J van der Vliet; Tanja D de Gruijl; Yvette van Kooyk; Mark A Exley
Journal:  Front Immunol       Date:  2018-09-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.